Treatment approaches in autoimmune pancreatitis (Review)
- Authors:
- Vlad Pădureanu
- Alice Nicoleta Drăgoescu
- Rodica Pădureanu
- Maria Magdalena Roșu
- Dumitru Rădulescu
- Dalia Dop
- Mircea Cătălin Forțofoiu
-
Affiliations: Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Anaesthesiology and Intensive Care, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Diabetes, Nutrition and Metabolic Diseases, County Clinical Emergency Hospital of Craiova, Craiova 200642, Romania, Department of Pediatrics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania, Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania - Published online on: December 21, 2023 https://doi.org/10.3892/br.2023.1714
- Article Number: 26
-
Copyright: © Pădureanu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Klöppel G, Lerch MM, Löhr M, et al: International consensus diagnostic criteria for autoimmune pancreatitis: Guidelines of the International Association of Pancreatology. Pancreas. 40:352–358. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Vinge-Holmquist O, Benth JŠ, Arnø E, Langbach O and Røkke O: Increased incidence and reduced mortality after first attack of acute pancreatitis over an 18-year period. Scand J Gastroenterol. 58:1534–1541. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Radulescu PM, Davitoiu DV, Baleanu VD, Padureanu V, Ramboiu DS, Surlin MV, Bratiloveanu TC, Georgescu EF, Streba CT, Mercut R, et al: Has COVID-19 Modified the weight of known systemic inflammation indexes and the new ones (MCVL and IIC) in the assessment as predictive factors of complications and mortality in acute pancreatitis? Diagnostics (Basel). 12(3118)2022.PubMed/NCBI View Article : Google Scholar | |
|
Rădulescu PM, Căluianu EI, Traşcă ET, Mercuţ D, Georgescu I, Georgescu EF, Ciupeanu-Călugăru ED, Mercuţ MF, Mercuţ R, Padureanu V, et al: The Impact of the COVID-19 Pandemic on Outcomes in Acute Pancreatitis: A Propensity Score Matched Study Comparing before and during the Pandemic. Diagnostics (Basel). 13(2446)2023.PubMed/NCBI View Article : Google Scholar | |
|
Sah RP, Pannala R, Chari ST, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, et al: Prevalence, diagnosis, and profile of autoimmune pancreatitis presenting with features of acute or chronic pancreatitis. Clin Gastroenterol Hepatol. 8:91–96. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Löhr JM, Beuers U, Vujasinovic M, Alvaro D, Frøkjær JB, Buttgereit F, Capurso G, Culver EL, de-Madaria E, Della-Torre E, et al: European guideline on IgG4-related digestive disease-UEG and SGF evidence-based recommendations. United European Gastroenterol J. 8:637–666. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, Azumi A, Bloch DB, Brugge WR, Carruthers MN, et al: Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 64:3061–3067. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Pădureanu V, Boldeanu MV, Streaţă I, Cucu MG, Siloşi I, Boldeanu L, Bogdan M, Enescu AŞ, Forţofoiu M, Enescu A, et al: Determination of VEGFR-2 (KDR) 604A>G polymorphism in pancreatic disorders. Int J Mol Sci. 18(439)2017.PubMed/NCBI View Article : Google Scholar | |
|
Sarles H, Sarles JC, Muratore R and Guien C: Chronic inflammatory sclerosis of the pancreas: An autonomous pancreatic disease? Am J Dig Dis. 6:688–698. 1961.PubMed/NCBI View Article : Google Scholar | |
|
Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K and Hayashi N: Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 40:1561–1568. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Notohara K, Kamisawa T, Fukushima N, Furukawa T, Tajiri T, Yamaguchi H, Aishima S, Fukumura Y, Hirabayashi K, Iwasaki E, et al: Guidance for diagnosing autoimmune pancreatitis with biopsy tissues. Pathol Int. 70:699–711. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chari ST, Kloeppel G, Zhang L, Notohara K, Lerch MM and Shimosegawa T: Autoimmune Pancreatitis International Cooperative Study Group (APICS). Histopathologic and clinical subtypes of autoimmune pancreatitis: The Honolulu consensus document. Pancreas. 39:549–554. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zamboni G, Lüttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P, Leins A, Longnecker D and Klöppel G: Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: A study on 53 resection specimens and 9 biopsy specimens. Virchows. Arch. 445:552–563. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Nishimori I, Tamakoshi A and Otsuki M: Research Committee on Intractable Diseases of the Pancreas, Ministry of Health, Labour and Welfare of Japan. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J Gastroenterol. 42 (Suppl 18):S6–S8. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Petzold G, Ellenrieder V and Neesse A: Autoimmune Pancreatitis in Germany: Rare but Relevant. Digestion. 96:185–186. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, Werner J, Bergmann F, Lerch MM, Mayerle J, et al: Clinical profile of autoimmune pancreatitis and its histological subtypes: An international multicenter survey. Pancreas. 40:809–814. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, et al: Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 139:140–148; quiz e12-3. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ito T, Kawa S, Matsumoto A, Kubota K, Kamisawa T, Okazaki K, Hirano K, Hirooka Y, Uchida K, Masuda A, et al: Risk factors for pancreatic stone formation in type 1 autoimmune pancreatitis: A long-term japanese multicenter analysis of 624 patients. Pancreas. 48:49–54. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Soliman H, Vullierme MP, Maire F, Hentic O, Ruszniewski P, Lévy P and Rebours V: Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective. United European Gastroenterol J. 7:1073–1083. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bennis R, Roy T, Atto YN and Colin MI: La maladie systémique à IgG4, une cause rare de pancréatite aigüe sévère. Louvain Med. 139:185–191. 2020. | |
|
Nikolic S, Lanzillotta M, Panic N, Brismar TB, Moro CF, Capurso G, Della Torre E, Löhr JM and Vujasinovic M: Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature. United European Gastroenterol J. 10:496–506. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Ikeura T, Manfredi R, Zamboni G, Negrelli R, Capelli P, Amodio A, Calió A, Colletta G, Gabbrielli A, Benini L, et al: Application of International Consensus Diagnostic Criteria to an Italian Series of Autoimmune Pancreatitis. United European Gastroenterol J. 1:276–284. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, Kim MH, Lévy P, Masamune A, Webster G and Shimosegawa T: International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 17:1–6. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L, Frulloni L, Go VL, Gress TM, Kim MH, et al: Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis. Gut. 62:1771–1776. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Kim HM, Chung MJ and Chung JB: Remission and relapse of autoimmune pancreatitis: Focusing on corticosteroid treatment. Pancreas. 39:555–560. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Pădureanu V, Caragea DC, Florescu MM, Vladu IM, Rădulescu PM, Florescu DN, Rădulescu D, Pădureanu R and Efrem IC: Role of the SARS-CoV2 infection in the evolution of acute pancreatitis (Review). Biomed Rep. 19(49)2023.PubMed/NCBI View Article : Google Scholar | |
|
Okazaki K, Kawa S, Kamisawa T, Ikeura T, Itoi T, Ito T, Inui K, Irisawa A, Uchida K, Ohara H, et al: Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2020. J Gastroenterol. 57:225–245. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, Nishino T, Notohara K, Nishimori I, Tanaka S, et al: Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 49:961–970. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Tacelli M, Celsa C, Magro B, Barresi L, Guastella S, Capurso G, Frulloni L, Cabibbo G and Cammà C: Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 17:1061–1072.e8. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yoon SB, Moon SH, Kim JH, Park JW, Kim SE and Kim MH: Determination of the duration of glucocorticoid therapy in type 1 autoimmune pancreatitis: A systematic review and meta-analysis. Pancreatology: May, 2021 (Epub ahead of print). | |
|
Brito-Zerón P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M and Stone JH: Therapeutic Approach to IgG4-Related Disease: A systematic review. Medicine (Baltimore). 95(e4002)2016.PubMed/NCBI View Article : Google Scholar | |
|
De Pretis N, Amodio A, Bernardoni L, Campagnola P, Capuano F, Chari ST, Crinò S, Gabbrielli A, Massella A, Topazian M and Frulloni L: Azathioprine maintenance therapy to prevent relapses in autoimmune. Clin Transl Gastroenterol. 8(e90)2017.PubMed/NCBI View Article : Google Scholar | |
|
Masaki Y, Nakase H, Tsuji Y, Nojima M, Shimizu K, Mizuno N, Ikeura T, Uchida K, Ido A, Kodama Y, et al: The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: A systematic review and meta-analysis. J Gastroenterol. 56:869–880. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bobircă A, Bobircă F, Ancuta I, Florescu A, Pădureanu V, Florescu DN, Pădureanu R, Florescu A and Mușetescu AE: Rheumatic immune-related adverse Events-A consequence of immune checkpoint inhibitor therapy. Biology (Basel). 10(561)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, et al: HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 47:615–620. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Nikolic S, Panic N, Hintikka ES, Dani L, Rutkowski W, Hedström A, Steiner C, Löhr JM and Vujasinovic M: Efficacy and safety of rituximab in autoimmune pancreatitis type 1: Our experiences and systematic review of the literature. Scand J Gastroenterol. 56:1355–1362. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Carruthers MN, Stone JH, Deshpande V and Khosroshahi A: Development of an IgG4-RD responder index. Int J Rheumatol. 2012(259408)2012.PubMed/NCBI View Article : Google Scholar | |
|
Pădureanu V, Florescu DN, Pădureanu R, Ghenea AE, Gheonea DI and Oancea CN: Role of antioxidants and oxidative stress in the evolution of acute pancreatitis (Review). Exp Ther Med. 23(197)2022.PubMed/NCBI View Article : Google Scholar | |
|
Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S and Stone JH: Rituximab for IgG4-Related Disease: A prospective, open-label trial. Ann Rheum Dis. 74:1171–1177. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Backhus J, Neumann C, Perkhofer L, Schulte LA, Mayer B, Seufferlein T, Müller M and Kleger A: A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. J Clin Med. 10(1329)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, Terrier B, Guillaud C, Carra-Dallière C, Renou F, et al: Long-Term efficacy and safety of rituximab in IgG4-Related disease: Data from a French Nationwide study of thirty-three patients. PLoS One. 12(e0183844)2017.PubMed/NCBI View Article : Google Scholar | |
|
De Marchi G, de Pretis N, Gabrieletto EM, Amodio A, Davì V, Crinò SF, Gabbrielli A, Ciccocioppo R and Frulloni L: Rituximab as maintenance therapy in type 1 autoimmune pancreatitis: An Italian Experience. Pancreas. 50:1363–1367. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, Levy MJ, Pearson RK, Petersen BT, Smyrk TC, et al: Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo clinic experience. Gut. 62:1607–1615. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu M and Hao M: Unique Properties of IgG4 antibody and its clinical application in autoimmune pancreatitis. Scand J Gastroenterol. 53:1121–1131. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 13:725–732. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA and King B: The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 147:814–826. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z and Baradaran B: Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 235:5903–5924. 2020.PubMed/NCBI View Article : Google Scholar | |
|
El-Shabrawi Y, Rath T and Heiligenhaus A: Janus kinase inhibitors: Next-Generation treatment for uveitis. Klin Monbl Augenheilkd. 239:695–701. 2022.PubMed/NCBI View Article : Google Scholar : (In English, German). | |
|
Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, Yang MC, Chen CS, Bloomston M, Ostrowski MC, et al: Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep. 7(1787)2017.PubMed/NCBI View Article : Google Scholar | |
|
Basyal B and KC P: Autoimmune Pancreatitis. In: StatPearls. StatPearls Publishing, Treasure Island, FL, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560769/. | |
|
Nista EC, De Lucia SS, Manilla V, Schepis T, Pellegrino A, Ojetti V, Pignataro G, Zileri Dal Verme L, Franceschi F, Gasbarrini A and Candelli M: Autoimmune Pancreatitis: From Pathogenesis to Treatment. Int J Mol Sci. 23(12667)2022.PubMed/NCBI View Article : Google Scholar | |
|
de Pretis N and Frulloni L: Autoimmune pancreatitis type 2. Curr Opin Gastroenterol. 36:417–420. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Poddighe D: Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations. World J Gastroenterol. 27:3825–3836. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Kawa S: The immunobiology of immunoglobulin G4 and complement activation pathways in IgG4-Related disease. Curr Top Microbiol Immunol. 401:61–73. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sugimoto M, Watanabe H, Asano T, Sato S, Takagi T, Kobayashi H and Ohira H: Possible Participation of IgG4 in the Activation of Complement in IgG4-Related disease with hypocomplementemia. Mod Rheumatol. 26:251–258. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhang L, Mao W, Liu D, Hu B, Lin X, Ran J, Li X and Hu J: Risk factors for drug-related acute pancreatitis: An analysis of the FDA adverse event reporting system (FAERS). Front Pharmacol. 14(1231320)2023.PubMed/NCBI View Article : Google Scholar | |
|
Venkatesh PG and Navaneethan U: Azathioprine induced pancreatitis in a patient with co-existing autoimmune pancreatitis and hepatitis. JOP. 12:250–254. 2011.PubMed/NCBI | |
|
Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O and Sorensen HT: Risk of acute pancreatitis in users of azathioprine: A population-based case-control study. Am J Gastroenterol. 98:1305–1308. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Sazonovs A, Stevens CR, Venkataraman GR, Yuan K, Avila B, Abreu MT, Ahmad T, Allez M, Ananthakrishnan AN, Atzmon G, et al: Large-scale sequencing identifies multiple genes and rare variants associated with Crohn's disease susceptibility. Nat Genet. 54:1275–1283. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Agboola AA, Mohamed KH, Syed M, Shiwlani S, Butt R, Reza RR, Haseeb M and Nasir H: Type 1 autoimmune pancreatitis masquerading as pancreatic head carcinoma. Cureus. 15(e47471)2023.PubMed/NCBI View Article : Google Scholar | |
|
Blaho M, Dítě P, Kunovský L and Kianička B: Autoimmune pancreatitis-An ongoing challenge. Adv Med Sci. 65:403–408. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bateman AC and Culver EL: Challenges and pitfalls in the diagnosis of IgG4-related disease. Semin Diagn Pathol: Nov, 2023 (Epub ahead of print). | |
|
Lanzillotta M, Della-Torre E, Wallace ZS, Stone JH, Karadag O, Fernández-Codina A, Arcidiacono PG, Falconi M, Dagna L and Capurso G: Efficacy and Safety of Rituximab for IgG4-Related Pancreato-Biliary Disease: A Systematic Review and Meta-Analysis. Pancreatology. 21:1395–1401. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Naghibi M, Ahmed A, al Badri AM, Bateman AC, Shepherd HA and Gordon JN: The successful treatment of IgG4-Positive colitis with adalimumab in a patient with IgG4-related sclerosing disease-a new subtype of aggressive colitis? J Crohns Colitis. 7:e81–e84. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Shirwaikar Thomas A and Chari ST: Immune checkpoint inhibitor-induced (Type 3) autoimmune pancreatitis. Curr Gastroenterol Rep. 25:255–259. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Lorenzo D, Vullierme MP and Rebours V: Antitumor necrosis factor therapy is effective for autoimmune pancreatitis type 2. Am J Gastroenterol. 115:1133–1134. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen C, Lu D, Sun T and Zhang T: JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: A patent review (2016-present). Expert Opin Ther Pat. 32:225–242. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Song H, Meng X, Li R, Leung PSC, Gershwin ME, Zhang S, Sun S and Song J: Autoimmune pancreatitis type 2 (idiopathic duct-centric pancreatitis): A comprehensive review. J Autoimmun. 140(103121)2023.PubMed/NCBI View Article : Google Scholar |
